Discovery of Novel Selective Norepinephrine Reuptake Inhibitors: 4-[3

May 12, 2010 - Charles Mann,† Casey C. McComas,†. Nicole R. Sullivan,. ) Taylor B. Spangler,. ) Albert J. Uveges,. ) Eugene J. Trybulski,†. Gart...
0 downloads 0 Views 2MB Size
Download PDF
J. Med. Chem. 2010, 53, 4511–4521 4511 DOI: 10.1021/jm100053t

Discovery of Novel Selective Norepinephrine Reuptake Inhibitors: 4-[3-Aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231)

)

)

)

)

)

)

David J. O’Neill,*,† Adedayo Adedoyin,§ Peter D. Alfinito,‡ Jenifer A. Bray,‡ Scott Cosmi,‡ Darlene C. Deecher,‡ Andrew Fensome,† Jim Harrison, Liza Leventhal, Charles Mann,† Casey C. McComas,† Nicole R. Sullivan, Taylor B. Spangler, Albert J. Uveges, Eugene J. Trybulski,† Garth T. Whiteside, and Puwen Zhang† Chemical Sciences, ‡Musculoskeletal Biology, and §Drug Safety and Metabolism, Pfizer Global Research & Development, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Neuroscience, PGRD, CN 8000, Princeton, New Jersey 08543 )

†

Received January 14, 2010

Structural modification of a virtual screening hit led to the identification of a new series of 4-[3-aryl-2,2dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols which are potent and selective inhibitors of the norepinephrine transporter over both the serotonin and dopamine transporters. One representative compound S-17b (WYE-103231) had low nanomolar hNET potency (IC50 =1.2 nM) and excellent selectivity for hNET over hSERT (>1600-fold) and hDAT (>600-fold). S-17b additionally had a good pharmacokinetic profile and demonstrated oral efficacy in rat models of ovariectomizedinduced thermoregulatory dysfunction and morphine dependent flush as well as the hot plate and spinal nerve ligation (SNL) models of acute and neuropathic pain.

Introduction a

The norepinephrine transporter (NET ) is a membrane bound protein which regulates the uptake of the neurotransmitter norepinephrine (NE) from the presynaptic cleft of noradrenergic neurons during synaptic transmission.1,2 It therefore plays an important role in regulating the physiological functions of NE, the deficiency of which has been implicated in a number of neurological disorders. NE reuptake inhibitors (NRIs) block the return of NE to the axon terminal, thereby maintaining its synaptic concentration resulting in a treatment for a range of CNS disorders.3 In the last 20 years, a number of monoamine neurotransmitter reuptake inhibitors have been approved for the treatment of neurological disorders such as depression and pain.4 More recently, selective NRIs such as reboxetine 1 and atomoxetine 2 have been used clinically for the alleviation of major depressive disorder and attention deficit hyperactivity disorder (ADHD), respectively.5,6 There is also evidence that these compounds may have efficacy in the

treatment of chronic pain including fibromyalgia and lower back pain.7,8

*To whom correspondence should be addressed. Phone: (860) 7156627. Fax: (860) 686-5256. E-mail: [email protected]. Address: Pfizer Global Research & Development, MS: 8220-3445, Eastern Point Road, Groton, Connecticut 06340. a Abbreviations: NE, norepinephrine; NET, norephinephrine transporter; NRI, norepinephrine reuptake inhibitor; CNS, central nervous system; SERT, serotonin transporter; DAT, dopamine transporter; hNET, human norepinephrine transporter; hSERT, human serotonin transporter; hDAT, human dopamine transporter; SAR, structureactivity relationship; LMS, liver microsomal stability; CYP450, cytochrome P450; hERG, human ether-a-go-go related gene; QTc, heartratecorrected QT interval; pk, pharmacokinetics; Clp, clearance; Vss, steady state volume of distribution; Cmax, maximum concentration; Tmax, time to maximum concentration; F%, percent bioavailability; AUC, area under the curve; OVX, ovariectomized; TST, tail-skin temperature; SNL, spinal nerve ligation.

Our previous reports have detailed efforts which resulted in the discovery of selective NRIs including cycloalkanol ethylamines,9 e.g. 3, benzimidazol-2-ones,10 e.g. 4, and indolin-2-ones 5.11 In our continuing effort to search for novel and selective NRIs, we have identified the N-aryl 2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl core, 6, via virtual screening and rational drug design approaches.12 Extensive SAR studies of this core have led to potent and selective NRI series. This report will cover the 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)yl]-1-(methylamino)butan-2-ols, their synthesis, in vitro SAR, and the in vivo efficacy of lead compound S-17b. Additional

r 2010 American Chemical Society

Published on Web 05/12/2010

pubs.acs.org/jmc

4512 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 11

O’Neill et al.

Scheme 1. Synthesis of N-Aryl-2,2-Dioxido-2,1,3-benzothiadiazol-1(3H)-yl Cores and Targets 9-15a

Reagents and conditions: (a) 2-fluoronitrobenzene, NaH, DMF; (b) H2, Pd/C, EtOAc; (c) sulfamide, sulfamic acid, diglyme, 190 °C; (d) HOR2alkyl-Br, DIAD, PPh3, THF; (e) MeNH2, EtOH, sealed tube, rt. a

Scheme 2. Synthesis of 4-[3-Aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(alkylamino)butan-2-ols 17-22a

a

Reagents and conditions: (a) but-3-en-1-ol, DIAD, PPh3, THF, rt; (b) m-CPBA, DCM, rt; (c) R3R4NH, EtOH, 100 °C, 3 min, microwave.

work incorporating this core to produce other chemical series will be disclosed in due course.

Scheme 3. Asymmetric Synthesis of 4-[3-Aryl-2,2-dioxido-2,1,3benzothiadiazol-1(3H)-yl]-1- (methylamino)butan-2-ols R-17a-j and S-17a-ja

Chemistry A synthetic route toward the preparation of the N-aryl 2,2dioxido-2,1,3-benzothiadiazol-1(3H)-yl cores and targets 9-15 is described in Scheme 1. Amine deprotonation of the substituted anilines 7a-j followed by addition of 2-fluoronitrobenzene resulted in nucleophilic substitution of the fluorine. Hydrogenation of the nitrobenzene intermediates resulted in dianilines 8a-j. Ring closure of 8a-j with sulfamide furnished cyclic 2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yls 6a-j. With these key cores in hand, target compounds 9-15 were easily accessible employing a Mitsonobu N-alkylation. This was exemplified with the N-2-fluorophenyl 2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl core 6b, which can be treated with a variety of substituted bromoalkyl alcohols. Subsequent halogenamine substitution with methylamine furnished target compounds 9-15. Mitsonobu N-alkylation of cores 6a-j with but-3-en-1-ol, Scheme 2, provided the intermediate alkenes 16a-j, which were epoxidized with m-CPBA, then typically used without isolation and ring-opened with alkylamines to provide targets 17-22. Compounds 17a-b were separated into the R- and S-enantiomers utilizing chiral preparative HPLC. The absolute configuration of each enantiomer was determined by asymmetric synthesis utilizing intermediates of known chirality, Scheme 3. This route was also used to prepare additional

a

Reagents and conditions: (a) (R)-4-tosyloxy-1,2-epoxybutane, K2CO3, acetone, rt; (b) (S)-4-bromo-1,2-epoxybutane, K2CO3, acetone, rt; (c) MeNH2, EtOH, 100 °C, 3 min, microwave.

analogues. Mitsonobu N-alkylation of a 2,2-dioxido-2,1,3benzothiadiazol-1(3H)-yl core with either the R or the S chiral epoxide provided R-24a-j and S-24a-j. Ring-opening with

Article

Journal of Medicinal Chemistry, 2010, Vol. 53, No. 11

4513

Table 1. Monoamine Reuptake Inhibition and Rat Metabolic Stability of N-2-Fluorophenyl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yls 9-23

a

Inhibition of norepinephrine uptake in MDCK-Net6 cells, stably transfected with human norepinephrine transporter (hNET). Desipramine (IC50 = 3.4 ( 1.6 nM) was used as a standard. b Inhibition of [3H] nisoxetine binding to MDCK-Net6 cells stably transfected with hNET. Desipramine (Ki = 2.1 ( 0.6 nM) was used as a standard. Compounds without standard errors are reported as an n of 1. c Inhibition of serotonin uptake in JAR cells, natively expressing human serotonin transporter (hSERT). Fluoxetine (IC50 = 9.4 ( 3.1 nM) was used as a standard. d Inhibition of [3H]WIN-35,428 binding to membranes from CHO cells expressing recombinant human dopamine transporter (hDAT). Mazindol (Ki = 22.1 ( 6.5 nM) was used as a standard. e Values in the parentheses are IC50 (nM). f LMS, liver microsomal stability.15

methylamine provided the desired targets R-17a-j and S-17a-j, respectively. Final compounds were converted to their hydrochloride salt prior to in vitro and in vivo testing. Results and Discussion In Vitro Characterization. Initial optimization of the N-aryl 2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl scaffold led to the identification of 9. This initial lead had excellent potency for hNET (IC50 = 1 nM) and good selectivity over hDAT and hSERT, Table 1, however 9 also displayed a low rodent metabolic half-life. The primary sites of metabolism were predicted13 and confirmed experimentally as demethylation of the amine as well as oxidation of the benzo and pendant phenyl rings. To address the metabolic instability in rodents, various structural modifications were made to block these sites of metabolism. Modification of the electronic and steric character of the amine side chain aimed at reducing dealkylation while maintaining or improving the hNET potency and selectivity was the focus of the work described in this report. Detailed experimental protocols for all assays discussed were reported previously.9,14 Analogues incorporating a methyl group along the propyl side chain, 10-13, resulted in an overall 7-600-fold drop in hNET functional potency with no increase in rat liver microsomal stability (LMS). While substitution proximal to the amine, 10, gave a 70-fold drop in hNET potency (IC50 = 72 nM),

incorporation of the methyl group at the center carbon of the propyl chain resulted in the greatest drop in potency (12, hNET IC50 =602 nM). The distal methyl analogue 13 caused the smallest reduction in hNET functional potency (IC50 = 7 nM). Incorporation of electronegative groups in the side chain, such as the β-fluoro analogue 14, reduced hNET potency (IC50 = 238 nM) without any improvement in rat metabolic stability. Extending the propyl side chain to four carbons provided compound 15 (IC50 = 4 nM), which had comparable in vitro potency and reduced hDAT selectivity when compared to 9. Interestingly, compound 17b, a fourcarbon chain analogue with a β-hydroxy group had improved rat LMS (t1/2 =9 min) while maintaining good hNET potency (IC50 = 10 nM) and excellent selectivity. Attempted introduction of the β-hydroxy substitution into the propyl chain led to degradation of the target compound. Oxidation of the alcohol, 17b, to the ketone, 23, led to an equally potent NRI with reduced metabolic stability. Compound 17b demonstrated improved metabolic stability while maintaining good hNET potency and selectivity versus hSERT and hDAT. In addition, introduction of the β-hydroxy group had a significant impact on clogP and tPSA values, which improved the drug-like properties of the series.16 A variety of β-hydroxy substituted analogues were synthesized on the N-phenyl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)yl core (Tables 2 and 3). As shown in Table 2, increasing the

4514 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 11 Table 2. NE Reuptake Inhibition and Rat Metabolic Stability of 4-[3Phenyl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(alkylamino)butan2-ols

compd

R

R1

hNET IC50 (nM)a

rat LMS t1/2 (min) b

17a 18 19 20 21 22

Me Et i-Pr c-Pr t-Bu Me

H H H H H Me

2 ( 0.2 196 ( 76 2255 ( 1489 9 ( 1.8 853 ( 298 481 ( 161

12 9 6 6 6 3

a Inhibition of norepinephrine uptake in MDCK-Net6 cells, stably transfected with human norepinephrine transporter (hNET). Desipramine (IC50 = 3.4 ( 1.6 nM) was used as a standard. b LMS, liver microsomal stability.

size of the N-alkyl group reduced hNET potency as well as rat LMS. The dimethylamino compound 22 showed minimal rat microsomal stability as might be expected. Interestingly, the cyclopropylamino derivative 20 demonstrated the smallest drop in hNET potency with an IC50 of 9 nM in the hNET functional assay while its isopropyl analogue 19 was over 100-fold less potent. The SAR of substitution around the pendant aryl ring was examined (Table 3). Compounds in this series were tested as single enantiomers. In general, the R-enantiomers were 29-fold less potent in the hNET assays than the corresponding S-enantiomers. While both enantiomers showed comparable hSERT selectivity, the R-enantiomers were less selective for hDAT. Compound S-17b was the most potent of the S-enantiomers tested (IC50 =1 nM) with excellent hNET selectivity versus hSERT (>1300-fold) and hDAT (>600-fold). Analogues S-17h and S-17i displayed similar profiles to S-17b (hNET IC50 95% chemical purity as determined by the above methods. 1-Phenyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide (6a). Compound 6a was prepared following the general procedure for 6b with N-(2-fluorophenyl)benzene-1,2-diamine being replaced with N-phenyl-o-phenylenediamine. MS (ES) m/z 245.2 ([M - H]þ). HRMS: calcd for C12H10N2O2S þ Hþ, 247.0536; found (ESI, [M þ H]þ), 247.0541. 1H NMR (DMSO-d6) δ 11.62 (br s, 1H), 7.49 (m, 5H), 6.91 (m, 3H), 6.57 (d, J = 7.54 Hz, 1H). General Procedure for the Synthesis of the Sulfamide Cores. 1-(2Fluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxide (6b). 2-Fluoroaniline (1.45 mL, 15 mmol) was dissolved in DMF (10 mL), and sodium hydride (0.58 g, 15 mmol) was added and the mixture was stirred for 30 min. 2-Fluoronitrobenzene (1.05 mL, 10 mmol) was added, and the mixture was stirred for 16 h. The mixture was quenched with saturated NH4Cl and diluted with ether. The mixture was washed with water, brine, dried over anhydrous magnesium sulfate, and concentrated. The crude product was purified via chromatography (Redisep, silica, gradient 5-30% ethyl acetate in hexane) to afford 1.4 g of 2-fluoro-N-(2-nitrophenyl)aniline (MS (ES) m/z 232.9), which was dissolved in ethyl acetate (20 mL), and 10% palladium on activated carbon (150 mg) was added. The mixture was shaken under a hydrogen atmosphere (40 psi) for 2 h. The mixture was filtered through a pad of celite and concentrated to give 1.2 g of N-(2-fluorophenyl)benzene-1,2-diamine (MS (ES) m/z 203.0) that was carried on directly to the next step. Dry diglyme (10 mL) was added to a flask equipped with a dropping funnel under a nitrogen atmosphere and brought to a vigorous reflux. N-(2-Fluorophenyl)benzene-1,2-diamine (1.2 g, 5.9 mmol) and sulfamide (0.68 g, 7.1 mmol) were dissolved in 5 mL of diglyme and placed in the dropping funnel. The mixture was added dropwise to the flask over 15 min, and then refluxing was continued for an additional 15 min. The mixture was cooled to ambient temperature and diluted with ether, washed with water, 2N HCl, water, and brine, dried over anhydrous magnesium sulfate, and concentrated. The crude product was purified via chromatography (Redisep, silica, gradient 5-50% (ethyl acetate containing 2% formic acid) in hexane) to afford 0.37 g of 1-(2-fluorophenyl)-1,3-dihydro-2,1,3benzothiadiazole 2,2-dioxide 6b (28%). MS (ES) m/z 262.9 ([M - H]þ); HRMS: calcd for C12H9FN2O2S þ Hþ, 265.0442; found (ESI, [M þ H]þ), 265.0444;

Article

Journal of Medicinal Chemistry, 2010, Vol. 53, No. 11

4517

Figure 2. Abatement of compound S-17b on morphine dependent flush in OVX Rats. Compound was dosed in accordance with the previously published protocol.22 N = 10 rats per dose.

Figure 3. Oral activity of compound S-17b on hot plate latency. Male, Sprague-Dawley rats, wt = 181-215 g, (n = 10/group). The hot plate was set at 52 °C and cut off was set at 30 s. Latency to nocifensive response was measured. S-17b was administered (po) as a solution in 2% Tween/0.5% methylcellulose (vehicle). Morphine was administered (sc) as a solution in 0.9% saline. Data shown are means ( SEM. 1 H NMR (DMSO-d6) δ 7.54 (m, 3H), 7.40-7.35 (m, 1H), 6.90 (m, 3H), 6.44 (d, J = 7.81 Hz, 1H). 1-(2-Chlorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxide (6c). Compound 6c was prepared following the general procedure for sulfamide synthesis with 2-fluoroaniline being replaced with 2-chloroaniline. MS (ES) m/z 278.8 ([M - H]þ). HRMS: calcd for C12H9ClN2O2S - Hþ, 279.0000; found (ESI, [M - H]þ), 279.0002. 1H NMR (DMSO-d6) δ 7.72 (m, 1H), 7.56 (m, 3H), 6.90 (m, 3H), 6.28 (d, J = 7.55 Hz, 1H). 1-(2-Methylphenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2Dioxide (6d). Compound 6d was prepared following the general procedure for sulfamide synthesis with 2-fluoroaniline being replaced with 2-methylaniline. MS (ES) m/z 261.0 ([M þ H]þ). HRMS: calcd for C13H12N2O2S - Hþ, 259.0547; found (ESI, [M - H]þ), 259.0546. 1H NMR (DMSO-d6) δ 11.62 (br s, 1H), 7.51 (m, 2H), 7.42 (m, 2H), 6.92 (m, 3H), 6.25 (d, J = 7.54 Hz, 1H), 2.21 (s, 3H). 1-(3-Methoxyphenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2Dioxide (6e). Compound 6e was prepared following the general procedure for sulfamide synthesis with 2-fluoroaniline being replaced with 3-methoxyaniline. MS (ES) m/z 276.9 ([M þ H]þ). HRMS: calcd for C13H12N2O3S - Hþ, 275.0496; found (ESI, [M - H]þ), 275.0494. 1H NMR (DMSO-d6) δ 11.64 (br s, 1H), 7.44 (m, 1H), 7.02 (m, 2H), 6.90 (m, 4H), 6.63 (m, 1H), 3.75 (s, 3H). 1-(4-Fluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2Dioxide (6f). Compound 6f was prepared following the general procedure for sulfamide synthesis with 2-fluoroaniline being replaced with 4-fluoroaniline.

MS (ES) m/z 263.0 ([M - H]þ). HRMS: calcd for C12H9FN2O2S - Hþ, 263.0296; found (ESI, [M - H]þ), 263.0295. 1H NMR (DMSO-d6) δ 11.65 (br s, 1H), 7.48 (m, 2H), 7.39 (m, 2H), 6.91 (m, 3H), 6.54 (d, J = 7.69 Hz, 1H). 1-(2,4-Difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2Dioxide (6g). Compound 6g was prepared following the general procedure for sulfamide synthesis with 2-fluoroaniline being replaced with 2,4-difluoroaniline. MS (ES) m/z 281.0 ([M - H]þ). HRMS: calcd for C12H8F2N2O2S - Hþ, 281.0202; found (ESI, [M - H]þ), 281.0207. 1H NMR (DMSO-d6) δ 11.80 (br s, 1H), 7.65 (m, 2H), 7.33 (m, 1H), 6.50 (m, 3H), 6.53 (d, J = 7.66 Hz, 1H). 1-(2,5-Difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2Dioxide (6h). Compound 6h was prepared following the general procedure for sulfamide synthesis with 2-fluoroaniline being replaced with 2,5-difluoroaniline. MS (ES) m/z 280.9 ([M - H]þ). HRMS: calcd for C12H8F2N2O2S - Hþ, 281.0202; found (ESI, [M - H]þ), 281.0204. 1H NMR (DMSO-d6) δ 11.82 (br s, 1H), 7.61 (m, 1H), 7.52 (m, 2H), 6.98 (m, 3H), 6.60 (d, J = 7.80 Hz, 1H). 1-(2,6-Difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2Dioxide (6i). Compound 6i was prepared following the general procedure for sulfamide synthesis with 2-fluoroaniline being replaced with 2,6-difluoroaniline. MS (ES) m/z 281.3 ([M - H]þ). HRMS: calcd for C12H8F2N2O2S þ Hþ, 283.0347; found (ESI, [M þ H]þ), 283.0347.; 1H NMR (DMSO-d6) δ 11.88 (br s, 1H), 7.73 (m, 1H), 7.42 (m, 2H), 6.98 (m, 3H), 6.56 (d, J = 7.80 Hz, 1H). 1-(3,4-Difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2Dioxide (6j). Compound 6j was prepared following the general procedure for sulfamide synthesis with 2-fluoroaniline being replaced with 3,4-difluoroaniline. MS (ES) m/z 280.8 ([M - H]þ). HRMS: calcd for C12H8F2N2O2S - Hþ, 281.0202; found (ESI, [M þ H]þ), 281.0203. 1H NMR (DMSO-d6) δ 11.78 (br s, 1H), 7.63 (m, 2H), 7.34 (m, 1H), 6.92(m, 3H), 6.65 (d, J = 7.95 Hz, 1H). 3-[3-(2-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)yl]-N-methylpropan-1-amine (9). 6b (0.37 g, 1.4 mmol) was dissolved in THF (10 mL). Triphenylphosphine (440 mg, 1.68 mmol) and 3-bromopropanol (0.12 mL, 1.4 mmol) were added, followed by diisopropylazodicarboxylate (0.33 mL, 1.68 mmol). The mixture was stirred for 16 h and then concentrated. Purification via chromatography (Redisep, silica, gradient 5-50% ethyl acetate in hexane) afforded 0.41 g of 1-(3-bromopropyl)3-(2-fluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide, which was immediately carried on to the next step. 1-(3-Bromopropyl)-3-(2-fluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide (0.4 g, 1.04 mmol) was dissolved in 8N methylamine in methanol (20 mL) and stirred for 16 h in a sealed flask. The mixture was concentrated in vacuo to give the crude product. The crude product was purified via chromatography (silica, 5% methanol

4518 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 11

O’Neill et al.

Figure 4. Oral activity of compound S-17b on SNL-induced mechanical hyperalgesia. Male, Sprague-Dawley rats (238-304 g, 9-10/group), 3 weeks postsurgery. Threshold to paw withdrawal was measured. S-17b was administered orally as a suspension of 0.5% methylcellulose plus 2% Tween in water. Gabapentin was used as a positive control and administered (ip) as a solution in 0.9% saline. Data shown are means ( SEM. * indicates a p value of e0.05 vs SNL/vehicle (ANOVA).

saturated with ammonia in chloroform) to give 350 mg of 3-[3-(2-fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)yl]-N-methylpropan-1-amine. The free base was dissolved in ether (10 mL) and treated with 1N hydrochloric acid in ether (1 equiv). The white precipitate was collected and dried under vacuum to provide 9. MS (ES) m/z 335.9 ([M þ H]þ). HRMS: calcd for C16H18FN3O2S þ Hþ, 336.1177; found (ESI, [M þ H]þ), 336.1177. 1H NMR (DMSO-d6) δ 8.85 (br s, 2H), 7.57 (m, 2H), 7.41 (m, 1H), 7.20 (m, 1H), 7.06 (m, 1H), 6.93 (m, 1H), 6.52 (d, J = 7.82 Hz, 1H), 3.95 (m, 2H), 2.99 (m, 2H), 2.5 (s, 3H), 2.09 (m, 2H). 3-[3-(2-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)yl]-N-methylbutan-2-amine (10). Compound 10 was prepared following the procedure for compound 9 with 3-bromopropanol being replaced with 3-bromobutan-1-ol. MS (ES) m/z 350.0 ([M þ H]þ). HRMS: calcd for C17H15FN2O þ Hþ, 350.1339; found (ESI, [M þ H]þ), 350.1338. 1H NMR (DMSO-d6) δ 8.82 (br s, 2H), 7.64 (m, 3H), 7.46 (m, 1H), 7.26 (m, 1H), 7.12 (m, 1H), 6.99 (m, 1H), 6.58 (d, J = 7.82 Hz, 1H), 3.38 (m, 1H), 2.55 (m, 3H), 2.26 (m, 2H), 1.98 (m, 2H), 1.33 (d, J = 6.54 Hz, 3H). (2R)-3-[3-(2-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-N,2-dimethylpropan-1-amine (11). Compound 11 was prepared following the procedure for compound 9 with 3-bromopropanol being replaced with (S)-3-bromo-2-methylpropan-1-ol. MS (ES) m/z 350.0 ([M þ H]þ). HRMS: calcd for C17H15FN2O þ Hþ, 350.1339; found (ESI, [M þ H]þ), 350.1335. 1H NMR (DMSO-d6) δ 8.79 (br s, 2H), 7.57 (m, 3H), 7.43 (m, 1H), 7.21 (m, 1H), 7.04 (m, 1H), 6.94 (m, 1H), 6.52 (d, J = 7.81 Hz, 1H), 3.88 (m, 1H), 3.72 (m, 1H), 3.02 (m, 1H), 2.89 (m, 1H), 2.52 (m, 3H), 1.06 (d, J = 6.67 Hz, 3H). (2S)-3-[3-(2-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-N,2-dimethylpropan-1-amine (12). Compound 12 was prepared following the procedure for compound 9 with 3-bromopropanol being replaced with (R)-3-bromo-2-methylpropan-1-ol. MS (ES) m/z 350.0 ([M þ H]þ). HRMS: calcd for C17H15FN2O þ Hþ, 350.1339; found (ESI, [M þ H]þ), 350.1337. 1H NMR (DMSO-d6) δ 8.79 (br s, 2H), 7.57 (m, 3H), 7.43 (m, 1H), 7.21 (m, 1H), 7.04 (m, 1H), 6.94 (m, 1H), 6.52 (d, J = 7.81 Hz, 1H), 3.88 (m, 1H), 3.72 (m, 1H), 3.02 (m, 1H), 2.89 (m, 1H), 2.52 (m, 3H), 1.06 (d, J = 6.67 Hz, 3H). (2S)-3-[3-(2-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-N,2-dimethylpropan-1-amine (13). Compound 13 was prepared following the procedure for compound 9 with 3-bromopropanol being replaced with 4-bromobutan-2-ol. MS (ES) m/z 350.0 ([M þ H]þ). HRMS: calcd for C17H15FN2O þ Hþ, 350.1339; found (ESI, [M þ H]þ), 350.1335. 1H NMR (DMSO-d6) δ 8.47 (br s, 2H), 7.64 (m, 1H), 7.52 (m, 1H), 7.41 (m, 1H), 7.20 (m, 1H), 7.05 (m, 1H), 6.92 (m, 1H), 6.53 (d,

J = 7.82 Hz, 1H), 3.02 (m, 2H), 2.53 (m, 3H), 2.31 (m, 2H), 2.11 (m, 1H), 1.48 (d, J = 6.92 Hz, 3H). 2,2-Difluoro-3-[3-(2-fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-N-methylpropan-1-amine (14). Compound 14 was prepared following the procedure for compound 9 with 3-bromopropanol being replaced with 2,2-difluoro-3-hydroxyN-methylpropanamide. The resulting impure solid was treated with borane-tetrahyrofuran complex (1 M in THF, 3 equiv) at 0 °C and then stirred for 2 h, quenched with dilute hydrochloric acid, basified (NaOH), and extracted with ethyl acetate. The organic layer was washed with water, dried (MgSO4), and evaporated. The residue was purified first via chromatography (Redisep, silica, gradient 0-100% ethyl acetate in hexane) and then by reverse phase HPLC. MS (ES) m/z 372.0 ([M þ H]þ). HRMS: calcd for C16H16F3N3O2S þ Hþ, 372.09881; found (ESI, [M þ H]þ), 372.0982. 1 H NMR (DMSO-d6) δ 9.45 (br s, 2H), 7.59 (m, 3H), 7.42 (m, 1H), 7.18 (m, 1H), 7.08 (m, 1H), 7.99 (m, 1H), 6.55 (d, J = 7.95 Hz, 1H), 4.58 (t, J=5.89 Hz, 2H), 3.82 (t, J=7.82 Hz, 2H), 2.31 (s, 3H). 4-[3-(2-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)yl]-N-methylbutan-1-amine (15). Compound 15 was prepared following the procedure for compound 9 with 3-bromopropanol being replaced with 4-bromobutan-1-ol. MS (ESI) m/z 350.1 ([M þ H]þ). HRMS: calcd for C17H20FN3O2S þ Hþ, 350.13330; found (ESI-FTMS, [M þ H]þ), 350.13369. 1H NMR (DMSO-d6) δ 8.26 (br s, 2H), 7.53 (m, 4H), 7.14 (m, 1H), 7.05 (m, 1H), 6.92 (m, 1H), 6.51 (d, J = 6.92 Hz, 1H), 3.86 (t, J=6.92 Hz, 2H), 2.90 (t, J=7.56 Hz, 2H), 2.49 (s, 3H), 1.79 (m, 2H), 1.66 (m, 2H). Achiral Route toward 17a and b. 1-(But-3-enyl)-3-(2-fluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxide (16b). 6b (0.45 g, 1.7 mmol) was dissolved in tetrahydrofuran (20 mL), and triphenylphosphine (0.54 g, 2 mmol) was added followed by 3-buten-1-ol (0.16 mL, 1.87 mmol) and diisopropyl azodicarboxylate (0.39 g, 2 mmol). The mixture was stirred for 18 h at 23 °C. The mixture was concentrated and purified via chromatography (Redisep, silica, gradient 0-50% ethyl acetate in hexane) to afford 0.44 g of 1-(but-3-enyl)-3-(2-fluorophenyl)-1,3-dihydro2,1,3-benzothiadiazole 2,2- dioxide. MS (ESI) m/z 318.8 ([M þ H]þ). HRMS: calcd for C16H15FN2O2S þ Naþ, 341.07304; found (ESI, [M þ Na]þ), 341.0727. 1 H NMR (DMSO-d6) δ 7.56 (m, 3H), 7.41 (m, 1H), 7.15 (m, 1H), 7.03 (m, 1H), 6.91 (m, 1H), 6.51 (d, J = 7.82 Hz, 1H), 5.87 (m, 1H), 5.16 (m, 1H), 5.06 (m, 1H), 3.88 (m, 2H), 2.51 (m, 2H). 4-(2,2-Dioxido-3-phenyl-2,1,3-benzothiadiazol-1(3H)-yl)1-(methylamino)butan-2-ol (17a). Compound 17a was prepared following the procedure for compound 17b. MS (ESI) m/z 348.1 ([M þ H]þ). HRMS: calcd for C17H21N3O3S þ Hþ, 348.1376; found (ESI, [M þ H]þ), 348.1381.

Article

H NMR (DMSO-d6) δ 8.69 (br s, 2H), 7.61 (m, 3H), 7.51 (m, 2H), 7.18 (m, 1H), 7.09 (m, 1H), 6.98 (m, 1H), 6.66 (d, J = 6.91 Hz, 1H), 5.69 (m, 1H), 3.96 (m, 3H), 3.05 (m, 1H), 2.90 (m, 1H), 2.55 (m, 3H), 2.00 (m, 1H), 1.85 (m, 1H). 4-[3-(2-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)yl]-1-(methylamino)butan-2-ol (17b). 16b (0.44 g, 1.64 mmol) was dissolved in CH2Cl2 (10 mL) at 23 °C. 3-Chlorobenzoperoxoic acid (1.02 g, 3.9 mmol) was added and the mixture allowed to stir for 18 h and then filtered and concentrated. The residue was diluted with EtOAc and washed with 10% NaHCO3 solution then brine. After drying with Na2SO4, the solution was concentrated and then 300 mg of the residue was dissolved in 10 mL of MeNH2 solution (8 M in EtOH). The solution was irradiated in a microwave cuvette at 100 °C for 3 min. The reaction mixture was concentrated and then loaded directly onto silica gel and purified via chromatography (Redisep, silica, gradient 0-10% 7 M ammonia/MeOH solution in dichloromethane) to afford 300 mg of racemic 17b. MS (ESI) m/z 366.6 ([M þ H]þ). HRMS: calcd for C17H20FN3O3S þ Hþ, 366.1288; found (ESI, [M þ H]þ), 366.1269. 1H NMR (DMSO-d6) δ 8.51 (br s, 2H), 7.53 (m, 4H), 7.12 (m, 1H), 7.07 (m, 1H), 6.91 (m, 1H), 6.51 (d, J = 7.82 Hz, 1H), 5.60 (m, 1H), 3.91 (m, 3H), 3.00 (m, 1H), 2.85 (m, 1H), 2.51 (s, 3H), 1.95 (m, 1H), 1.80 (m, 1H). (2R)-4-(2,2-Dioxido-3-phenyl-2,1,3-benzothiadiazol-1(3H)-yl)1-(methylamino)butan-2-ol (R-17a) and (2S)-4-(2,2-Dioxido-3phenyl-2,1,3-benzothiadiazol-1(3H)-yl)-1-(methylamino)butan-2-ol (S-17a). Compounds R-17a and S-17a were prepared following the procedure for compounds R-17b and S-17b. R-17a: MS (ESI) m/z 348.1 ([M þ H]þ). HRMS: calcd for C17H21N3O3S þ Hþ, 348.1376; found (ESI, [M þ H]þ), 348.1381. 1 H NMR (DMSO-d6) δ 8.65 (br s, 2H), 7.66 - 7.56 (m, 3H), 7.51 (m, 2H), 7.18 (m, 1H), 7.09 (m, 1H), 6.98 (m, 1H), 6.67 (d, J = 7.81 Hz, 1H), 5.68 (m, 1H), 3.96 (m, 3H), 3.05 (m, 1H), 2.90 (m, 1H), 2.55 (m, 3H), 2.00 (m, 1H), 1.85 (m, 1H). S-17a: MS (ESI) m/z 348.1 ([M þ H]þ). HRMS: calcd for C17H21N3O3S þ Hþ, 348.1376; found (ESI, [M þ H]þ), 348.1381. 1 H NMR (DMSO-d6) δ 8.65 (br s, 2H), 7.66 - 7.56 (m, 3H), 7.51 (m, 2H), 7.18 (m, 1H), 7.09 (m, 1H), 6.98 (m, 1H), 6.67 (d, J = 7.81 Hz, 1H), 5.68 (m, 1H), 3.96 (m, 3H), 3.05 (m, 1H), 2.90 (m, 1H), 2.55 (m, 3H), 2.00 (m, 1H), 1.85 (m, 1H). (2R)-(4-[3-(2-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (R-17b) and (2S)-(4-[3-(2Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]1-(methylamino)butan-2-ol (S-17b). Approximately 300 mg of racemic 17b was dissolved in 4 mL of methanol. Then 200 μL of the resulting solution was repetitively injected onto the supercritical fluid chromatography instrument, and the baseline resolved enantiomers were separately collected using the conditions described below. The chiral purity of each enantiomer was determined under the same supercritical fluid chromatography conditions using a 250 mm  4.6 mm i.d. column at 2.0 mL/min flow rate using Chiralpak AS-H 5 analytical supercritical fluid chromatography (Berger Instruments, Inc. Newark, DE). Both enantiomers were found to be >99.9% enantiomerically pure. R-17b: MS (ESI) m/z 366.1 ([M þ H]þ). HRMS: calcd for C17H20FN3O3S þ Hþ, 366.1288; found (ESI, [M þ H]þ), 366.1289. 1 H NMR (DMSO-d6) δ 8.47 (br s, 2H), 7.63 (m, 1H), 7.54 (m, 2H), 7. 42 (m, 1H), 7.14 (m, 1H), 7.07 (m, 1H), 6.93 (m, 1H), 6.52 (d, J=7.95 Hz, 1H), 5.60 (d, J=6.02 Hz, 1H), 3.91 (m, 3H), 3.00 (m, 1H), 2.85 (m, 1H), 2.51 (s, 3H), 1.95 (m, 1H), 1.80 (m, 1H). S-17b: MS (ESI) m/z 365.9 ([M þ H]þ). HRMS: calcd for C17H20FN3O3S þ Hþ, 366.1288; found (ESI, [M þ H]þ), 366.1290. 1H NMR (DMSO-d6) δ 8.47 (br s, 2H), 7.63 (m, 1H), 7.54 (m, 2H), 7. 42 (m, 1H), 7.14 (m, 1H), 7.07 (m, 1H), 6.93 (m, 1H), 6.52 (d, J = 7.95 Hz, 1H), 5.60 (d, J = 6.02 Hz, 1H), 3.91 (m, 3H), 3.00 (m, 1H), 2.85 (m, 1H), 2.51 (s, 3H), 1.95 (m, 1H), 1.80 (m, 1H). Asymmetric Route to Compounds R-17c-j. (2R)-(4-[3-(2-Chlorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ol (R-17c). Compound R-17c was prepared following the procedure for compound R-17i. 1

Journal of Medicinal Chemistry, 2010, Vol. 53, No. 11

4519

MS (ESI) m/z 381.6 ([M þ H]þ). HRMS: calcd for C17H20ClN3O3S þ Hþ, 382.0987; found (ESI, [M þ H]þ), 382.0990. 1H NMR (DMSO-d6) δ 8.61 (br s, 2H), 7.80 (m, 1H), 7.67 (m, 1H), 7.60 (m, 1H), 7.18 (m, 1H), 7.08 (m, 1H), 6.93 (m, 1H), 6.41 (d, J = 7.55 Hz, 1H), 5.68 (m, 1H), 3.96 (m, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.86 (m, 1H). (2R)-(4-[3-(2-Methylphenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (R-17d). Compound R-17d was prepared following the procedure for compound R-17i. MS (ESI) m/z 361.7 ([M þ H]þ). HRMS: calcd for C18H23N3O3S þ Hþ, 362.1533; found (ESI, [M þ H]þ), 362.1538. 1H NMR (DMSO-d6) δ 8.63 (br s, 2H), 7.54 (m, 2H), 7.44 (m, 1H), 7.38 (m, 1H), 7.18 (m, 1H), 7.08 (m, 1H), 6.92 (m, 1H), 6.31 (d, J = 7.82 Hz, 1H), 5.67 (m, 1H), 3.97 (m, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 2.21 (s, 3H), 2.01 (m, 1H), 1.86 (m, 1H). (2R)-(4-[3-(3-Methoxyphenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (R-17e). Compound R-17e was prepared following the procedure for compound R-17i. MS (ESI) m/z 377.7 ([M þ H]þ). HRMS: calcd for C18H23N3O4S þ Hþ, 378.1482; found (ESI, [M þ H]þ), 378.1490. 1H NMR (DMSO-d6) δ 8.54 (br s, 2H), 7.54 (m, 1H), 7.18 (m, 2H), 7.09 (m, 2H), 6.99 (m, 2H), 6.73 (d, J=7.80 Hz, 1H), 5.66 (d, J= 5.97 Hz, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (s, 3H), 1.99 (m, 1H), 1.85 (m, 1H). (2R)-(4-[3-(4-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (R-17f). Compound R-17f was prepared following the procedure for compound R-17i. MS (ESI) m/z 365.6 ([M þ H]þ). HRMS: calcd for C17H20FN3O3S þ Hþ, 366.1282; found (ESI, [M þ H]þ), 378.1291. 1H NMR (DMSO-d6) δ 8.62 (br s, 2H), 7.57 (m, 2H), 7.48 (m, 2H), 7.18 (m, 1H), 7.09 (m, 1H), 6.98 (m, 1H), 6.62 (m, 1H), 5.68 (m, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.85 (m, 1H). (2R)-(4-[3-(2,4-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ol (R-17g). Compound R-17g was prepared following the procedure for compound R-17i. MS (ESI) m/z 383.6 ([M þ H]þ). HRMS: calcd for C17H19F2N3O3S þ Hþ, 384.1188; found (ESI, [M þ H]þ), 384.1193. 1H NMR (DMSO-d6) δ 8.62 (br s, 2H), 7.69 (m, 2H), 7.37 (m, 1H), 7.18 (m, 1H), 7.11 (m, 1H), 6.98 (m, 1H), 6.61 (d, J = 7.84 Hz, 1H), 5.68 (d, J=5.84 Hz, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.85 (m, 1H). (2R)-(4-[3-(2,5-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (R-17h). Compound R-17h was prepared following the procedure for compound R-17i. MS (ESI) m/z 383.6 ([M þ H]þ). HRMS: calcd for C17H19F2N3O3S þ Hþ, 384.1188; found (ESI, [M þ H]þ), 384.1189. 1H NMR (DMSO-d6) δ 8.59 (br s, 2H), 7.60 (m, 3H), 7.18 (m, 1H), 7.12 (m, 1H), 6.98 (m, 1H), 6.68 (d, J=7.87 Hz, 1H), 5.67 (d, J= 6 Hz, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.85 (m, 1H). (2R)-(4-[3-(2,6-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (R-17i). 6i (0.15 g, 0.5 mmol) was dissolved in acetone (5 mL), and potassium carbonate (0.14 g, 1.0 mmol) was added followed by (R)-2-(oxiran-2-yl)ethyl 4-tosylate (0.24 g, 1.0 mmol). The mixture was stirred for 18 h at 50 °C in a sealed vial and then diluted with EtOAc (100 mL) and washed with water (2) and brine and then dried (Na2SO4). After concentration, the residue was dissolved in 10 mL of MeNH2 solution (8 M in EtOH). The solution was irradiated in a microwave cuvette at 100 °C for 3 min. The reaction mixture was concentrated and then loaded directly onto silica gel and purified via chromatography (Redisep, silica, gradient 0-100% of 10% 7 M ammonia in MeOH/dichloromethane) to afford 59 mg of R-17i. MS (ESI) m/z 383.6 ([M þ H]þ). HRMS: calcd for C17H19F2N3O3S þ Hþ, 384.1188; found (ESI, [M þ H]þ), 384.1191. 1H NMR (DMSO-d6) δ 8.65 (br s, 2H), 7.77 (m, 1H), 7.45 (m, 2H), 7.21 (m, 1H), 7.12 (m, 1H), 6.99 (m, 1H), 6.64 (d, J = 7.80 Hz, 1H), 5.69 (d, J = 5.97 Hz, 1H), 3.96 (m, 3H), 3.05 (m, 1H), 2.90 (m, 1H), 2.55 (m, 3H), 2.00 (m, 1H), 1.85 (m, 1H).

4520 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 11

(2R)-(4-[3-(3,4-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (R-17j). Compound R-17j was prepared following the procedure for compound R-17i. MS (ESI) m/z 383.6 ([M þ H]þ). HRMS: calcd for C17H19F2N3O3S þ Hþ, 384.1188; found (ESI, [M þ H]þ), 384.1190. 1H NMR (DMSO-d6) δ 8.61 (br s, 2H), 7.70 (m, 2H), 7.41 (m, 1H), 7.18 (m, 1H), 7.12 (m, 1H), 7.00 (m, 1H), 6.75 (d, J = 7.85 Hz, 1H), 5.68 (d, J=5.99 Hz, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.85 (m, 1H). Asymmetric Route to Compounds S-17c-j. (2S)-(4-[3-(2-Chlorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ol (S-17c). Compound S-17c was prepared following the procedure for compound S-17i. MS (ESI) m/z 381.6 ([M þ H]þ). HRMS: calcd for C17H20ClN3O3S þ Hþ, 382.0987; found (ESI, [M þ H]þ), 382.0993. 1H NMR (DMSO-d6) δ 8.61 (br s, 2H), 7.80 (m, 1H), 7.67 (m, 1H), 7.60 (m, 1H), 7.18 (m, 1H), 7.08 (m, 1H), 6.93 (m, 1H), 6.41 (d, J = 7.55 Hz, 1H), 5.68 (m, 1H), 3.96 (m, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.86 (m, 1H). (2S)-(4-[3-(2-Methylphenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (S-17d). Compound S-17d was prepared following the procedure for compound S-17i. MS (ESI) m/z 361.8 ([M þ H]þ). HRMS: calcd for C18H23N3O3S þ Hþ, 362.1533; found (ESI, [M þ H]þ), 362.1538. 1H NMR (DMSO-d6) δ 8.63 (br s, 2H), 7.54 (m, 2H), 7.44 (m, 1H), 7.38 (m, 1H), 7.18 (m, 1H), 7.08 (m, 1H), 6.92 (m, 1H), 6.31 (d, J = 7.82 Hz, 1H), 5.67 (m, 1H), 3.97 (m, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 2.21 (s, 3H), 2.01 (m, 1H), 1.86 (m, 1H). (2S)-(4-[3-(3-Methoxyphenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (R-17e). Compound R-17e was prepared following the procedure for compound R-17i. MS (ESI) m/z 378.1 ([M þ H]þ). HRMS: calcd for C18H23N3O4S þ Hþ, 378.1482; found (ESI, [M þ H]þ), 378.1484. 1H NMR (DMSO-d6) δ 8.54 (br s, 2H), 7.54 (m, 1H), 7.18 (m, 2H), 7.09 (m, 2H), 6.99 (m, 2H), 6.73 (d, J=7.80 Hz, 1H), 5.66 (d, J= 5.97 Hz, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (s, 3H), 1.99 (m, 1H), 1.85 (m, 1H). (2S)-(4-[3-(4-Fluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (S-17f). Compound S-17f was prepared following the procedure for compound S-17i. MS (ESI) m/z 365.7 ([M þ H]þ). HRMS: calcd for C17H20FN3O3S þ Hþ, 366.1282; found (ESI, [M þ H]þ), 378.1287. 1H NMR (DMSO-d6) δ 8.62 (br s, 2H), 7.57 (m, 2H), 7.48 (m, 2H), 7.18 (m, 1H), 7.09 (m, 1H), 6.98 (m, 1H), 6.62 (m, 1H), 5.68 (m, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.85 (m, 1H). (2S)-(4-[3-(2,4-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (S-17g). Compound S-17g was prepared following the procedure for compound S-17i. MS (ESI) m/z 383.6 ([M þ H]þ). HRMS: calcd for C17H19F2N3O3S þ Hþ, 384.1188; found (ESI, [M þ H]þ), 384.1194. 1H NMR (DMSO-d6) δ 8.62 (br s, 2H), 7.69 (m, 2H), 7.37 (m, 1H), 7.18 (m, 1H), 7.11 (m, 1H), 6.98 (m, 1H), 6.61 (d, J = 7.84 Hz, 1H), 5.68 (d, J=5.84 Hz, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.85 (m, 1H). (2S)-(4-[3-(2,5-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (S-17h). Compound S-17h was prepared following the procedure for compound S-17i. MS (ESI) m/z 383.6 ([M þ H]þ). HRMS: calcd for C17H19F2N3O3S þ Hþ, 384.1188; found (ESI, [M þ H]þ), 384.1194. 1H NMR (DMSO-d6) δ 8.59 (br s, 2H), 7.60 (m, 3H), 7.18 (m, 1H), 7.12 (m, 1H), 6.98 (m, 1H), 6.68 (d, J=7.87 Hz, 1H), 5.67 (d, J= 6 Hz, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.85 (m, 1H). (2S)-(4-[3-(2,6-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (S-17i). 6i (0.15 g, 0.5 mmol) was dissolved in acetone (5 mL), and potassium carbonate (0.14 g, 1 mmol) was added followed by S(-)-4-bromo-1,2-epoxybutane (0.15 g, 1 mmol). The mixture was stirred for 18 h at 50 °C in a sealed vial and then diluted with EtOAc (100 mL) and washed with

O’Neill et al.

water (2) and brine and then dried (Na2SO4). After concentration, the residue was dissolved in 10 mL of MeNH2 solution (8 M in EtOH). The solution was irradiated in a microwave cuvette at 100 °C for 3 min. The reaction mixture was concentrated and then loaded directly onto silica gel and purified via chromatography (Redisep, silica, gradient 0-100% of 10% 7 M ammonia in MeOH/dichloromethane) to afford 69 mg of S-17i. MS (ESI) m/z 383.6 ([M þ H]þ). HRMS: calcd for C17H19F2N3O3S þ Hþ, 384.1188; found (ESI, [M þ H]þ), 384.1194. 1H NMR (DMSO-d6) δ 8.65 (br s, 2H), 7.77 (m, 1H), 7.45 (m, 2H), 7.21 (m, 1H), 7.12 (m, 1H), 6.99 (m, 1H), 6.64 (d, J = 7.80 Hz, 1H), 5.69 (d, J = 5.97 Hz, 1H), 3.96 (m, 3H), 3.05 (m, 1H), 2.90 (m, 1H), 2.55 (m, 3H), 2.00 (m, 1H), 1.85 (m, 1H). (2S)-(4-[3-(3,4-Difluorophenyl)-2,2-dioxido-2,1,3-benzothiadiazol1(3H)-yl]-1-(methylamino)butan-2-ol (S-17j). Compound S-17j was prepared following the procedure for compound S-17j. MS (ESI) m/z 384.2 ([M þ H]þ). HRMS: calcd for C17H19F2N3O3S þ Hþ, 384.1188; found (ESI, [M þ H]þ), 384.1192. 1H NMR (DMSO-d6) δ 8.61 (br s, 2H), 7.70 (m, 2H), 7.41 (m, 1H), 7.18 (m, 1H), 7.12 (m, 1H), 7.00 (m, 1H), 6.75 (d, J = 7.85 Hz, 1H), 5.68 (d, J=5.99 Hz, 1H), 3.96 (m, 3H), 3.8 (s, 3H), 3.03 (m, 1H), 2.88 (m, 1H), 2.55 (m, 3H), 1.99 (m, 1H), 1.85 (m, 1H). 4-(2,2-Dioxido-3-phenyl-2,1,3-benzothiadiazol-1(3H)-yl)-1-(ethylamino)butan-2-ol (18). Compound 18 was prepared following the procedure for compound 17b, replacing MeNH2 with EtNH2. MS (ESI) m/z 362.1 ([M þ H]þ). HRMS: calcd for C18H23N3O3S þ Hþ, 362.1533; found (ESI, [M þ H]þ), 362.1540. 1H NMR (DMSO-d6) δ 8.51 (br s, 2H), 7.61 (m, 3H), 7.50 (m, 2H), 7.18 (m, 1H), 7.10 (m, 1H), 6.98 (m, 1H), 6.67 (d, J = 6.92 Hz, 1H), 5.64 (d, J = 6.02 Hz, 1H), 3.97 (m, 3H), 3.05 (m, 1H), 2.94 (m, 2H), 2.89 (m, 1H), 2.01 (m, 1H), 1.78 (m, 1H), 1.20(t, J = 7.31 Hz, 3H). 4-(2,2-Dioxido-3-phenyl-2,1,3-benzothiadiazol-1(3H)-yl)-1-(isopropylamino)butan-2-ol (19). Compound 19 was prepared following the procedure for compound 17b, replacing MeNH2 with i PrNH2. MS (ESI) m/z 376.1 ([M þ H]þ). HRMS: calcd for C19H25N3O3S þ Hþ, 376.1689; found (ESI, [M þ H]þ), 376.1695. 1H NMR (DMSO-d6) δ 8.41 (br s, 2H), 7.62 (m, 3H), 7.50 (m, 2H), 7.18 (m, 1H), 7.10 (m, 1H), 6.98 (m, 1H), 6.67 (d, J = 7.82 Hz, 1H), 5.62 (d, J = 6.02 Hz, 1H), 3.97 (m, 3H), 3.29 (m, 1H), 3.05 (m, 1H), 2.88 (m, 1H), 2.03 (m, 1H), 1.89 (m, 1H), 1.22 (m, 6H). 1-(Cyclopropylamino)-4-(2,2-dioxido-3-phenyl-2,1,3-benzothiadiazol-1(3H)-yl)butan-2-ol (20). Compound 20 was prepared following the procedure for compound 17b, replacing MeNH2 with cPrNH2. MS (ESI) m/z 374.1 ([M þ H]þ). HRMS: calcd for C19H23N3O3S þ Hþ, 374.1533; found (ESI, [M þ H]þ), 374.1537. 1H NMR (DMSO-d6) δ 8.82 (br s, 2H), 7.62 (m, 3H), 7.50 (m, 2H), 7.19 (m, 1H), 7.10 (m, 1H), 6.98 (m, 1H), 6.67 (d, J = 7.81 Hz, 1H), 5.62 (m, 1H), 3.97 (m, 3H), 3.18 (m, 1H), 2.99 (m, 1H), 2.69 (m, 1H), 2.02 (m, 1H), 1.89 (m, 1H), 0.86 (m, 2H), 0.71(m, 2H). 1-(tert-Butylamino)-4-(2,2-dioxido-3-phenyl-2,1,3-benzothiadiazol-1(3H)-yl)butan-2-ol (21). Compound 21 was prepared following the procedure for compound 17b, replacing MeNH2 with tBuNH2. MS (ESI) m/z 390.2 ([M þ H]þ). HRMS: calcd for C20H27N3O3S þ Hþ, 390.1846; found (ESI, [M þ H]þ), 390.1850. 1H NMR (DMSO-d6) δ 8.60 (br s, 1H), 8.40 (br s, 1H), 7.62 (m, 3H), 7.50 (m, 2H), 7.20 (m, 1H), 7.10 (m, 1H), 6.99 (m, 1H), 6.67 (d, J = 7.94 Hz, 1H), 5.62 (m, J = 5.90 Hz, 1H), 3.97 (m, 3H), 3.05 (m, 1H), 2.83 (m, 1H), 2.07 (m, 1H), 1.90 (m, 1H), 1.29 (s, 9H). 1-(Dimethylamino)-4-(2,2-dioxido-3-phenyl-2,1,3-benzothiadiazol-1(3H)-yl)butan-2-ol (22). Compound 22 was prepared following the procedure for compound 17b, replacing MeNH2 with Me2NH. MS (ESI) m/z 362.1 ([M þ H]þ). HRMS: calcd for C18H23N3O3S þ Hþ, 362.1533; found (ESI, [M þ H]þ), 362.1536. 1H NMR (DMSO-d6) δ 9.41 (br s, 1H), 7.62 (m, 3H), 7.50 (m, 2H), 7.18 (m, 1H), 7.10 (m, 1H), 6.99 (m, 1H), 6.67 (d, J = 7.95 Hz,

Article

1H), 5.78 (m, J = 6.15 Hz, 1H), 4.08 (m, 1H), 3.95 (m, 2H), 3.13 (m, 2H), 2.79(s, 6H), 1.96 (m, 1H), 1.86 (m, 1H). 4-(2,2-Dioxido-3-phenyl-2,1,3-benzothiadiazol-1(3H)-yl)1-(methylamino)butan-2-one (23). 17b (90 mg, 0.25 mmol) and di-tert-butyl dicarbonate (59 mg, 0.26 mmol) were stirred in dichloromethane (5 mL) in a sealed vial at room temperature for 18 h. The reaction mixture was concentrated and then loaded directly onto silica gel and purified via chromatography, providing a clear oil of which 50 mg (0.11 mmol) was stirred with Dess-Martin periodinane (68 mg, 0.16 mmol) in dichloromethane (5 mL) in a sealed vial at room temperature for 18 h. The reaction mixture was concentrated and then loaded directly onto silica gel and purified via chromatography to afford a clear oil, which was dissolved in diethyl ether/methanol. 4N HCl in dioxane was added and a precipitate slowly formed. The reaction was filtered to afford 23 mg of 23 as a white solid. MS (ESI) m/z 346.0 ([M þ H]þ). HRMS: calcd for C17H19N3O3S þ Hþ, 346.1220; found (ESI, [M þ H]þ), 346.1223. 1H NMR (DMSO-d6) δ 8.91 (br s, 2H), 7.61 (m, 3H), 7.50 (m, 2H), 7.20 (m, 1H), 7.10 (m, 1H), 6.99 (m, 1H), 6.67 (d, J = 7.94 Hz, 1H), 4.12 (m, 4H), 3.10 (m, 2H), 2.52(s, 3H).

Journal of Medicinal Chemistry, 2010, Vol. 53, No. 11

(11)

(12) (13)

(14)

(15) (16) (17)

(18)

Acknowledgment. We thank the Wyeth scientists whose work contributed to the program described in this manuscript: The Women’s Health & Musculoskeletal Biology and Neuroscience departments provided assay data,the Chemical Technologies group provided stability data and performed chiral resolutions, the Structural Biology & Computational Chemistry group provided computational support. Additional members of the project team are acknowledged for helpful discussions. Supporting Information Available: Analytical HPLC purity data is provided for all tested compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

(19) (20) (21) (22)

References (1) Gether, U.; Andersen, P. H.; Larsson, O. M.; Schousboe, A. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol. Sci. 2006, 27, 375–383. (2) Iversen, L. Neurotransmitter transporters and their impact on the development of psychopharmacology. Br. J. Pharmacol. 2006, 147, S82–S88. (3) Babu, R. P. K.; Maita, S. M. Norepinephrine Reuptake Inhibitors for Depression, ADHD and other Neuropsychiatric Disorders. Heterocycles 2006, 69, 539–567. (4) Walter, M. W. Monoamine reuptake inhibitors: highlights of recent research developments. Drug Dev. Res. 2005, 65 (3), 97–118. (5) Hajos, M.; Fleishaker, J. C.; Filipiak-Reisner, J. K.; Brown, M. T.; Wong, E. H. F. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev. 2004, 10 (1), 23–44. (6) Kratochvil, C. J.; Vaughan, B. S.; Daughton, J. M.; MayfieldJorgensen, M. L.; Burke, W. J. Atomoxetine in the treatment of attention deficit hyperactivity disorder. Expert Rev. Neurother. 2004, 4 (4), 601–611. (7) Berigan, T. Use of atomoxetine adjunctively in fibromyalgia syndrome. Can. J. Psychiatry 2004, 49, 499–500. (8) Krell, H. V.; Leuchter, A. F.; Cook, I. A.; Abrams, M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005, 46, 379–384. (9) Mahaney, P. E.; Gavrin, L. K.; Trybulski, E.; Stack, G. P.; Vu, A. T.; Cohn, S. T.; Fei, Y.; Belardi, J. K.; Santilli, A. A.; Sabatucci, J. P.; Leiter, J.; Johnston, G. H.; Bray, J. A.; Burroughs, K. D.; Cosmi, S. A.; Leventhal, L.; Koury Elizabeth, J.; Zhang, Y.; Mugford, C. A.; Ho, D. M.; Rosezweig-Lipson, S. J.; Platt, B.; Smith, V. A.; Deecher, D. C. Structure-Activity Relationships of the Cycloalkanol Ethylamine Scaffold: Discovery of Selective Norepinephrine Reuptake Inhibitors. J. Med. Chem. 2008, 51, 4038–4049. (10) Zhang, P.; Terefenko, E. A.; Bray, J.; Deecher, D.; Fensome, A.; Harrison, J.; Kim, C.; Koury, E.; Mark, L.; McComas, C. C.; Mugford, C. A.; Trybulski, E. J.; Vu, A. T.; Whiteside, G. T.; Mahaney, P. E. 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3dihydro-2H-benzimidazol-2-ones: Potent, Selective, and Orally

(23)

(24) (25)

(26) (27) (28) (29)

(30) (31)

4521

Efficacious Norepinephrine Reuptake Inhibitors. J. Med. Chem. 2009, 52 (18), 5703–5711. McComas, C. C.; Vu, A. T.; Mahaney, P. E.; Cohn, S. T.; Fensome, A.; Marella, M. A.; Nogle, L.; Trybulski, E. J.; Ye, F.; Zhang, P.; Alfinito, P.; Bray, J.; Johnston, G.; Koury, E.; Deecher, D. C. Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 4929–4931. This work shall be disclosed in a separate communication. Cruciani, G.; Carosati, E.; De Boeck, B.; Ethirajulu, K.; Mackie, C.; Howe, T.; Vianello, R. MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist. J. Med. Chem. 2005, 48, 6970–6979. Di, L.; Kerns, E. H.; Ma, X. J.; Huang, Y.; Carter, G. T. Applications of high throughput microsomal stability assay in drug discovery. Comb. Chem. High Throughput Screening 2008, 11 (6), 469–476. This was used as a screening assay (n of 1) to rank compounds and assess their potential for further characterization. Gleeson, M. P. Generation of a Set of Simple, Interpretable ADMET Rules of Thumb. J. Med. Chem. 2008, 51 (4), 817–834. Holbrook, M.; Malik, M.; Shah, R. R.; Valentin, J.-P. Drug induced shortening of the QT/QTc interval: An emerging safety issue warranting further modelling and evaluation in drug research and development? J. Pharmacol. Toxicol. Methods 2009, 59 (1), 21–28. Experimental protocols for in vivo pK work discussed was reported in: Gavrin, L. K.; Mahaney, P. E.; Jenkins, D.; Nogle, L. M.; Mugford, C. A.; Huselton, C.; Leiter, J.; Johnston, G. H.; Bray, J. A.; Burroughs, K. D.; Cosmi, S. A.; Alfinito, P.; Ho, D. M.; Deecher, D. C.; Trybulski, E. J., Discovery of WAY-260022, a Potent and Selective Inhibitor of the Norepinephrine Transporter. ACS Med. Chem. Lett. 2010, DOI: 10.1021/ml100009p. McEwen, B. S.; Alves, S. E. Estrogen actions in the central nervous system. Endocr. Rev. 1999, 20 (3), 279–307. Riedel, W.; Dorward, P. K.; Korner, P. I. Central adrenoceptors modify hypothalamic thermoregulatory patterns of autonomic activity in conscious rabbits. J. Auton. Nerv. Syst. 1981, 3, 525–533. Rintamaki, H.; Lahti, H.; Hissa, R. Feather position of the pigeon after intrahypothalamic injections of noradrenaline, 5-hydroxytryptamine and carbachol. Experientia 1981, 37, 1173–1175. Deecher, D. C.; Alfinito, P. D.; Leventhal, L.; Cosmi, S.; Johnston, G. H.; Merchenthaler, I.; Winneker, R. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 2007, 148, 1376–1383. Loprinzi, C. L.; Kugler, J. W.; Sloan, J. A.; Mailliard, J. A.; LaVasseur, B. I.; Barton, D. L.; Novotny, P. J.; Dakhil, S. R.; Rodger, K.; Rummans, T. A.; Christensen, B. J. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000, 356, 2059–2063. Pertovaara, A. Noradrenergic pain modulation. Prog. Neurobiol. 2006, 80 (2), 53–83. Holden, J. E.; Schwartz, E. J.; Proudfit, H. K. Microinjection of morphine in the A7 catecholamine cell group produces opposing effects on nociception that are mediated by alpha 1- and alpha 2-adrenoceptors. Neuroscience 1999, 91, 979–990. Ren, K.; Dubner, R. Descending modulation in persistent pain: an update. Pain 2002, 100, 1–6. Ren, K.; Ruda, M. A. Descending modulation of Fos expression after persistent peripheral inflammation. NeuroReport 1996, 7, 2186–2190. D’Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation. J. Pharm. Exp. Ther. 1941, 72, 74–79. Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulet, J. M.; Gottshall, S. L.; Mark, L.; Pearson, M. S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Elsemore, D. A.; Toth, M.; Koetzner, L.; Whiteside, G. T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia, and catalepsy. Neuropharmacology 2005, 48, 658–672. Kim, S. H.; Chung, J. M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50, 355–363. Sullivan, N. R.; Leventhal, L.; Harrison, J.; Smith, V. A.; Cummons, T. A.; Spangler, T. B.; Sun, S.-C. L., P.; Uveges, A. J.; Strassle, B. W.; Piesla, M. J.; Ramdass, R.; Barry, A.; Schantz, J.; Adams, W.; Whiteside, G. T.; Adedoyin, A.; Jones, P. G. Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-azabicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain. J. Pharmacol. Exp. Ther. 2007, 322, 1294–1304.